TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12610739
Drug: Hydrochloride salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochloride salt (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Study: 12610739
Drug: Cinchona alkaloid
Normalized name: Cinchona alkaloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by slow 4-h intravenous infusion)
Study: 12610739
Drug: Hydrochloride salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochloride salt (8 mg/kg quinine base every 8 h by intrarectal administration)
Study: 12610739
Drug: Cinchona alkaloid
Normalized name: Cinchona alkaloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinchona alkaloid mixture (8 mg/kg quinine base every 8 h by intrarectal administration)
Study: 8629065
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy alone
Study: 8629065
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy plus antibiotics
Study: 8629065
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy followed by diethylcarbamazine citrate (DEC)
Study: 8629065
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy plus antibiotics followed by DEC
Study: 8629065
Drug: Hygienic measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygienic measures combined with good foot care and local antibiotic/antifungal cream application
Study: 15927414
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (controls)
Study: 29081179
Drug: ILK-CSC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILK-CSC injection (1×10^5 cells/30 μl)
Study: 29081179
Drug: Ad-null-CSC injection
Normalized name: Nullo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad-null-CSC injection (1×10^5 cells/30 μl)
Study: 23438054
Drug: Collagen/ORC/silver therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen/ORC/silver therapy
Study: 23438054
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (standard treatment)
Study: 11360851
Drug: Xylose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylose 5% infusion
Study: 11360851
Drug: Electrolyte infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte infusion
Study: 9428058
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) treatment for 4 weeks
Study: 8098392
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of 125 mL of an aminoacid mixture (Synthamin 14 without electrolytes) over 5 min (2.1 g per min)
Study: 8098392
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of 50 mL of aminoacids over 5 min
Study: 3318991
Drug: Reality orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reality orientation followed by reminiscence therapy
Study: 24557441
Drug: EMLA(®) cream
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA(®) cream
Study: 24557441
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (EMLA(®) cream and traditional anesthetic)
Study: 20390497
Drug: m-DOT (modified-directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-DOT (modified-directly observed therapy)
Study: 17522928
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: overnight infusion and a bolus of colloid before induction of anesthesia, followed by a bolus just before pneumoperitoneum (PP)
Study: 17522928
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: overnight infusion and a colloid bolus before anesthesia
Study: 17522928
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: received only infusion during operation
Study: 10227461
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and autologous stem cell support
Study: 10227461
Drug: Melphalan-prednisone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan-prednisone (initial therapy)
Study: 6337618
Drug: Sulconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulconazole 1% cream
Study: 30556374
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded group (loaded on the same day as implant insertion)
Study: 30556374
Drug: Conventionally loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally loaded group (loaded 3 months after implant insertion)
Study: 24669841
Drug: Recombinant IFN‐γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IFN‐γ (rIFN‐γ, 100 μg s.c., thrice a week) for 2 weeks
Study: 24669841
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal therapy
Study: 22982081
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy (PST: in-person or telehealth delivery)
Study: 18973065
Drug: Rivastigmine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (1.5 mg once a day increment over 4 weeks to 3 mg twice daily)
Study: 16076046
Drug: Exogenous activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous activated protein C (drotrecogine alpha) included in therapy for sepsis
Study: 12602460
Drug: Fosinopril 5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 5-20 mg/day
Study: 9882083
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexketoprofen trometamol 25 mg
Study: 9882083
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexketoprofen trometamol 12.5 mg
Study: 9882083
Drug: dipyrone 575
Approvals — FDA: no, EMA: no, PMDA: no
Description: dipyrone 575 mg
Study: 7925220
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g boiled carrots
Study: 7925220
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g boiled carrots
Study: 7925220
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g boiled carrots
Study: 7925220
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g boiled carrots with lactic acid
Study: 2635834
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SI)
Study: 2635834
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OI)
Study: 24841105
Drug: Sodium pyruvate
Normalized name: Sodium Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium pyruvate (0.1 g·kg(‐1) of body mass)
Study: 3118755
Drug: Nitroglycerin discs
Normalized name: DISC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin discs (30 mg)
Study: 24187865
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy at acupoint until appearance of skin eruptions
Study: 24187865
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy along channel until appearance of skin eruptions
Study: 24187865
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy at acupoint without appearance of skin eruptions
Study: 24187865
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy along channel without appearance of skin eruptions
Study: 21894054
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement 1,520 IU/daily
Study: 21894054
Drug: Ultraviolet radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultraviolet radiation B (UVB) 6 min weekly
Study: 15482031
Drug: Ultrasound-guided thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided thrombin injection
Study: 3043370
Drug: Imipramine (low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (low, medium, and high doses)
Study: 31337437
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change intervention with classroom-based session (CBS) and SMS reminders to brush teeth twice daily
Study: 25923275
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline spray and a 3‐day course of antibiotics (either amoxicillin/clavulanate or levofloxacin)
Study: 18653753
Drug: High-carbohydrate (HC)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate (HC) diet (7 g.kg(‐1).day(‐1))
Study: 18653753
Drug: Low-carbohydrate (LC)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate (LC) diet (2.9 g.kg(‐1).day(‐1))
Study: 14503833
Drug: Crown-down technique
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown-down technique with Greater Taper files (GT files) (Group 3)
Study: 14503833
Drug: Step-back technique
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step-back technique with Greater Taper files (GT files) (Group 4)
Study: 10915748
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg/d orally for 12 weeks
Study: 10915748
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg/d plus famciclovir 500 mg 3 times a day orally for 12 weeks
Study: 8831468
Drug: Methylphenidate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate administered twice daily at a dose of .30 mg/kg
Study: 8831468
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered according to the same schedule in identical pill form
Study: 6585285
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (0.5 mg)
Study: 6585285
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (1.0 mg)
Study: 6585285
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (2.0 mg)
Study: 31184016
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens in combination with Urtica dioiccus 160/120 mg twice daily for 3 months
Study: 31184016
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens 320 mg once a day for 3 months
Study: 12610802
Drug: Topical Tripterygium
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tripterygium wilfordii (TW)
Study: 10730525
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin (0.2 mg/kg initially, then 0.1 mg/kg every 12 hours for 2 more doses)
Study: 7723643
Drug: Large fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large fluid replacement (Large FR) - 1330 +/- 60 ml of a 6% carbohydrate solution (79 +/- 4 g)
Study: 7723643
Drug: Small fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small fluid replacement (Small FR) - 200 +/- 10 ml of a 40% maltodextrin solution (79 +/- 4 g)
Study: 7723643
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (CHO) - 6% carbohydrate solution (79 +/- 4 g)
Study: 2119958
Drug: Intravenous tetrandrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tetrandrine (0.12 to 0.21 g)
Study: 2119958
Drug: Intravenous tetrandrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tetrandrine
Study: 31168688
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg BD
Study: 26787637
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI)
Study: 21596588
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered 5 minutes before exsanguination and inflation of the tourniquet (ABT)
Study: 21596588
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administered 1 minute after inflation of the tourniquet (AAT)
Study: 17196059
Drug: Noradrenergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine
Study: 17196059
Drug: Serotonin-norepinephrine reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine
Study: 2929979
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual nifedipine
Study: 26761270
Drug: Combination cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cognitive behavioral therapy and medication management algorithm (COMB)
Study: 20657612
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of the renin-angiotensin system
Study: 10413893
Drug: Sodium monofluorophosphate
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium monofluorophosphate (MFP) 15 mg F/day for 18 months
Study: 10413893
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) 30 mg F/day for 18 months
Study: 10413893
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) 30 mg F/day
Study: 10413893
Drug: Sodium monofluorophosphate
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium monofluorophosphate (MFP) 15 mg F/day
Study: 1900225
Drug: thrombin-antithrombin III
Normalized name: Thrombin-antithrombin III complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: thrombin-antithrombin III complex levels greater than 6 ng/l
Study: 6132852
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg intramuscularly
Study: 7065559
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg orally
Study: 6132852
Drug: Bethanechol, 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol, 0.07 mg/kg subcutaneously
Study: 28257378
Drug: 0.2 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/day fluocinolone acetonide (FAc)
Study: 27281531
Drug: TEV‐48125 675/225
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV‐48125 675/225 mg
Study: 27281531
Drug: TEV‐48125 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV‐48125 900 mg
Study: 22840457
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (GBT + conventional treatment)
Study: 24286408
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (control group)
Study: 17691587
Drug: Fe‐59 labeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐59 labeled iron(III)‐hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron
Study: 17691587
Drug: Fe‐59 labeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe‐59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl
Study: 12011578
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk providing 25 g/day of protein
Study: 10445772
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg/kg and placebo infusion
Study: 10445772
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (remifentanil 1 microg/kg and infusion of 0.2 microg/kg/min)
Study: 10445772
Drug: Alfentanil 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 7 microg/kg and placebo infusion
Study: 7796715
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg i.v. cocaine
Study: 1756260
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate (HDMA) at doses of 480, 800, 1280, and 1600 mg/d
Study: 1756260
Drug: High-dose megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose megestrol acetate (HDMA)
Study: 25406967
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ready‐to‐eat meals enriched with liquid fish oil
Study: 25406967
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as microencapsulated fish oil powder and regular meals
Study: 9642510
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g/d
Study: 9642510
Drug: MMF 3
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3 g/d
Study: 19958860
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEpo) 200 U/kg daily for 3 consecutive days
Study: 12201939
Drug: Intravesical IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical IFN gamma (0.7 mg per week for 8 weeks)
Study: 8567768
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (Norditropin, 12 IU/day, i.m., for 7 days)
Study: 25301816
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of excessive drinking and drug use
Study: 17717235
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL water
Study: 17717235
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL water
Study: 17717235
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 300 mL vs 50 mL water
Study: 11724848
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Isolator system and MYCO/F Lytic bottle
Study: 3076051
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride therapy
Study: 7980801
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment E
Study: 7980801
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy S
Study: 3060193
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg three times a day for 1 week, then 40 mg three times a day for 4 weeks
Study: 28947468
Drug: High DHA
Normalized name: Fish Oil/Stevia Extract 850 MG-10 MG Oral Packet [COROMEGA CHILD BRAIN & BODY HIGH DHA OMEGA-3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High DHA fish oil capsules
Study: 28947468
Drug: Control capsules
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsules without DHA
Study: 26373743
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus acidophilus, Enterococcus faecium and Bifidobacterium infantum) at a dose of 0.6 × 107 colony‐forming units twice daily
Study: 22647247
Drug: Fish protein
Normalized name: Fish Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish protein supplement (3 g/d for the first 4 weeks and 6 g/d for the last 4 weeks)
Study: 21638149
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g ginger extracts
Study: 1336762
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 200 mg daily for five days, then 200 mg twice weekly for six months
Study: 1336762
Drug: Intravaginal clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal clotrimazole 200 mg ovules daily for five days, then 200 mg twice weekly for six months
Study: 1336762
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole after discontinuation of therapy
Study: 1336762
Drug: Intravaginal clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal clotrimazole after discontinuation of therapy
Study: 18345398
Drug: Cilazapril alone
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril alone or cilazapril/hydrochlorothiazide/amlodipine combination therapy